J&J makes small I&I acquisition to enter competitive IL-13, TSLP arena
Johnson & Johnson said Thursday it will pay $850 million in cash for Proteologix, a relatively unknown private biotech working on treatments for immune-mediated diseases, including the crowded field of atopic dermatitis. The deal …